FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmacology and concerns a circulating drug carrier. The carrier contains polyethylene glycol modified phospholipid presented by general formula 
or its pharmaceutically acceptable salt: wherein X represents as follows 
or 
; and n represents an integer 30 to 150 wherein R1 represents a residue of saturated unbranched fatty acid having 17 to 22 carbon atoms, and 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl glycerol. Polyethylene glycol modified phospholipid is found in the amount of 30 wt % - 50 wt % of total weight of lipids in the carrier. What is also presented is a pharmaceutical composition containing the carrier described above and a drug.
EFFECT: group of inventions prolongs a circulation time and respectively improves the efficacy of the drug.
6 cl, 19 dwg, 5 tbl, 49 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ACTIVATOR OF CANCER CELL INTRACELLULAR NUCLEASE | 1998 |
|
RU2183460C2 |
| METHOD OF T-CELL ACTIVATION/PROLIFERATION | 2019 |
|
RU2806549C2 |
| NEW OLIGONUCLEOTIDES CONJUGATES AND USE THEREOF | 2012 |
|
RU2599449C1 |
| DISPOSABLE SYSTEM FOR STERILE OBTAINING OF LIPIDS AND NUCLEIC ACIDS PARTICLES | 2012 |
|
RU2642640C2 |
| NUCLEIC ACID COMPLEXES AS LIGANDS OF VESICAL ENDOTHELIAL GROWTH FACTOR (VEGF) | 1997 |
|
RU2177950C2 |
| STABLE COMPOSITIONS OF LIPIDS AND LIPOSOMES | 2015 |
|
RU2738060C2 |
| MEANS FOR INHIBITING PROTEINKINASE 3 EXPRESSION | 2007 |
|
RU2553561C2 |
| CATIONIC LIPIDS | 2018 |
|
RU2782218C2 |
| LIPID NANOPARTICLES FOR IN VIVO MEDICINAL PRODUCTS DELIVERY AND THEIR USE | 2020 |
|
RU2799045C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANIONIC DRUG, AND A METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2721558C2 |
